About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Apoe
apolipoprotein E
MGI:88057
171 phenotypes from 11 alleles in 26 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Apoeshl/Apoeshl
B6.KOR-Apoeshl 		increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
C3.KOR-Apoeshl 		increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
C.KOR-Apoeshl 		increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoeshl
involves: BALB/c * KOR 		alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
involves: C3H/He * KOR 		alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
involves: C57BL/6 * KOR 		alopecia J:54051
atherosclerotic lesions J:54051
increased circulating cholesterol level J:54051
premature death J:54051
xanthoma J:54051
Apoeshl/Apoeshl
KOR-Apoeshl 		abnormal nursing J:75488
increased circulating cholesterol level J:75488
increased susceptibility to atherosclerosis J:75488
xanthoma J:75488
Apoeshl/Apoetm1Unc
involves: 129P2/OlaHsd * KOR 		increased circulating cholesterol level J:54051
xanthoma J:54051
ApoeTg(rtTA)1Gaga/ApoeTg(rtTA)1Gaga
involves: 129S1/Sv * C57BL/6J 		increased circulating cholesterol level J:136987
increased susceptibility to atherosclerosis J:136987
Apoetm1.1Khw/Apoetm1.1Khw
involves: 129S4/SvJae * C57BL/6 * FVB/N 		normal homeostasis/metabolism phenotype J:71838
Apoetm1.1Mae/Apoetm1.1Mae
Tg(Fabp4-cre)1Rev/0
B6.Cg-Apoetm1.1Mae Tg(Fabp4-cre)1Rev 		decreased cardiac muscle triglyceride level J:219838
decreased cholesterol level J:219838
decreased circulating cholesterol level J:219838
decreased circulating glucose level J:219838
decreased circulating insulin level J:219838
decreased circulating triglyceride level J:219838
decreased epididymal fat pad weight J:219838
decreased liver cholesterol level J:219838
decreased liver triglyceride level J:219838
decreased macrophage cell number J:219838
decreased skeletal muscle triglyceride level J:219838
decreased triglyceride level J:219838
decreased white fat cell lipid droplet size J:219838
decreased white fat cell size J:219838
improved glucose tolerance J:219838
increased cholesterol level J:219838
increased insulin sensitivity J:219838
increased macrophage cell number J:219838
Apoetm1Bres/Apoe+
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J) 		abnormal digestive system physiology J:2809
increased circulating cholesterol level J:2809
Apoetm1Bres/Apoetm1Bres
B6.129P2-Apoetm1Bres 		abnormal circulating cholesterol level J:68574
atherosclerotic lesions J:68574
xanthoma J:68574
Apoetm1Bres/Apoetm1Bres
either: (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * C57BL/6J) 		abnormal cerebral cortex morphology J:42426
abnormal circulating LDL cholesterol level J:2809
abnormal digestive system physiology J:2809
abnormal hippocampus morphology J:42426
abnormal neuron morphology J:42426
increased circulating cholesterol level J:2809, J:42426
increased circulating VLDL cholesterol level J:2809
increased susceptibility to atherosclerosis J:2809
increased triglyceride level J:2809
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6 		atherosclerotic lesions J:29950
increased circulating cholesterol level J:29950
increased susceptibility to atherosclerosis J:43846
xanthoma J:43846
Apoetm1Bres/Apoetm1Bres
involves: 129P2/OlaHsd * C57BL/6 * NIH Black Swiss 		atherosclerotic lesions J:42927
decreased circulating HDL cholesterol level J:42927
increased circulating cholesterol level J:42927
increased circulating triglyceride level J:42927
Apoetm1Khw/Apoetm1Khw
involves: 129S4/SvJae * C57BL/6 		increased circulating cholesterol level J:75681
increased circulating LDL cholesterol level J:75681
increased circulating triglyceride level J:75681
increased circulating VLDL cholesterol level J:75681
Apoetm1Lmh/Apoe+
involves: 129S7/SvEvBrd * C57BL/6 		abnormal lipid homeostasis J:22347
atherosclerotic lesions J:22347
increased circulating cholesterol level J:22347
increased circulating HDL cholesterol level J:22347
increased circulating VLDL cholesterol level J:22347
Apoetm1Lmh/Apoetm1Lmh
involves: 129S7/SvEvBrd * C57BL/6 		abnormal lipid homeostasis J:22347
increased circulating cholesterol level J:22347
increased circulating HDL cholesterol level J:22347
increased circulating VLDL cholesterol level J:22347
xanthoma J:24054
Apoetm1Unc/Apoe+
involves: 129P2/OlaHsd * C57BL/6 		increased circulating triglyceride level J:16573
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc 		abnormal adrenal cortex morphology J:60585
abnormal adrenal gland morphology J:60585
abnormal adrenal medulla morphology J:60585
abnormal cell-mediated immunity J:125366
abnormal dendritic cell physiology J:125366
abnormal gland physiology J:60585
abnormal kindling response J:118390
abnormal lipid level J:125366
abnormal locomotor behavior J:71062
abnormal myelin sheath morphology J:106368
abnormal response to new environment J:71062
abnormal sciatic nerve morphology J:106368
abnormal spatial learning J:71062
abnormal synaptic vesicle morphology J:118390
abnormal thermal nociception J:106368
atherosclerotic lesions J:61287
decreased brown adipose tissue mass J:60585
decreased circulating leptin level J:60585
decreased epididymal fat pad weight J:60585
decreased exploration in new environment J:60585
decreased startle reflex J:71062
hypersecretion of corticosterone J:60585
hypopituitarism J:60585
increased anxiety-related response J:60585
increased CD4-positive, alpha-beta T cell number J:125366
increased circulating cholesterol level J:61287
increased fluid intake J:60585
increased food intake J:60585
increased susceptibility to parasitic infection J:125366
Apoetm1Unc/Apoetm1Unc
B6.129P2-Apoetm1Unc/J 		abnormal aorta wall morphology J:101576, J:142083
abnormal B cell activation J:133606
abnormal basilar membrane morphology J:101576
abnormal blood flow velocity J:108154
abnormal blood vessel physiology J:60364
abnormal bone structure J:111209
abnormal CD4-positive, alpha-beta T cell number J:47027, J:108154
abnormal circulating cholesterol level J:73202
abnormal cochlea morphology J:101576
abnormal enzyme/coenzyme activity J:73202
abnormal eye electrophysiology J:70245, J:84688
abnormal glomerular capillary thrombosis J:125978
abnormal immune serum protein physiology J:61564
abnormal immune system morphology J:47027
abnormal immune system physiology J:61564
abnormal kidney arterial blood vessel morphology J:125978
abnormal liver physiology J:104609
abnormal lung hysteresivity J:136630
abnormal lung volume J:136630
abnormal nitric oxide homeostasis J:298071
abnormal nucleotide metabolism J:338121
abnormal osteoblast physiology J:111209
abnormal pulmonary alveolus morphology J:136630
abnormal renal glomerulus morphology J:125978
abnormal retina inner nuclear layer morphology J:70245
abnormal skeleton physiology J:111209
abnormal spatial learning J:120203
abnormal spiral modiolar artery morphology J:101576
abnormal stria vascularis morphology J:101576
abnormal T cell number J:47027
abnormal tectorial membrane morphology J:101576
abnormal vascular smooth muscle physiology J:338121
abnormal vasodilation J:298071
arteriosclerosis J:108154
atherosclerotic lesions J:60364, J:73202, J:91058, J:97385, J:101576, J:105736, J:108154, J:142083
blood vessel inflammation J:91058
cardiac hypertrophy J:108154
cochlear ganglion degeneration J:101576
cochlear inner hair cell degeneration J:101576
cochlear outer hair cell degeneration J:101576
deafness J:101576
decreased body length J:136630
decreased body weight J:60364, J:108154
decreased circulating glucose level J:73202
decreased circulating HDL cholesterol level J:91058
decreased circulating homocysteine level J:73202
decreased circulating triglyceride level J:93987
decreased follicular B cell number J:133606
decreased hematocrit J:108154
decreased interferon-gamma secretion J:47027
decreased marginal zone B cell number J:133606
decreased susceptibility to atherosclerosis J:226403
decreased susceptibility to type IV hypersensitivity reaction J:61564
decreased systemic vascular resistance J:108154
decreased vasodilation J:101576
dilated glomerular capillary J:125978
expanded mesangial matrix J:125978
hyperlipidemia J:101576
impaired blood-brain barrier function J:69455
impaired muscle relaxation J:60364
impaired olfaction J:89344
increased airway resistance J:136630
increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased autoantibody level J:133606
increased B cell number J:133606
increased bone mineral density of vertebrae J:111209
increased bone trabecula number J:111209
increased bone volume J:111209
increased cardiac output J:108154
increased cardiac stroke volume J:108154
increased cholesterol efflux J:226403
increased circulating cholesterol level J:73202, J:91058, J:97385, J:101576, J:104609, J:125978, J:133606
increased circulating HDL cholesterol level J:226403
increased circulating LDL cholesterol level J:91058, J:93987, J:101576
increased circulating triglyceride level J:73202, J:91058, J:101576
increased circulating VLDL cholesterol level J:91058, J:93987, J:101576
increased compact bone thickness J:111209
increased heart weight J:108154
increased IgM level J:61564
increased immunoglobulin level J:133606
increased lung compliance J:136630
increased marginal zone B cell number J:133606
increased or absent threshold for auditory brainstem response J:101576
increased spleen weight J:61564
increased susceptibility to atherosclerosis J:43846, J:101576
increased susceptibility to systemic lupus erythematosus J:133606
increased susceptibility to weight gain J:136630
increased T-helper 2 cell number J:47027
increased thigmotaxis J:120203
increased trabecular bone volume J:111209
kidney microaneurysm J:125978
mesangiolysis J:125978
organ of Corti degeneration J:101576
oxidative stress J:97385, J:298071
premature death J:73202
renal glomerulus lipidosis J:125978
skin lesions J:73202
spiral modiolar artery stenosis J:101576
thin retina inner nuclear layer J:70245
thin retina outer nuclear layer J:70245
vascular stenosis J:101576
xanthoma J:43846, J:73202
Apoetm1Unc/Apoetm1Unc
B6.Cg-Apoetm1Unc Faslpr 		increased anti-double stranded DNA antibody level J:133606
increased anti-nuclear antigen antibody level J:133606
increased circulating cholesterol level J:133606
increased immunoglobulin level J:133606
increased susceptibility to atherosclerosis J:133606
increased susceptibility to systemic lupus erythematosus J:133606
Apoetm1Unc/Apoetm1Unc
either: B6.129P2-Apoetm1Unc/J or (involves: 129P2/OlaHsd * C57BL/6J * ICR) 		abnormal spatial learning J:100975
normal behavior/neurological phenotype J:100975
decreased vertical activity J:100975
normal nervous system phenotype J:55835, J:100975
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd 		abnormal circulating cholesterol level J:48202
abnormal dendrite morphology J:101973
abnormal susceptibility to atherosclerosis J:154332
decreased cerebral infarct size J:133156
decreased vasodilation J:154332
increased anxiety-related response J:101973
increased circulating cholesterol level J:48202
increased circulating corticosterone level J:101973
increased startle reflex J:101973
increased susceptibility to atherosclerosis J:107390
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		atherosclerotic lesions J:66419
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 		abnormal astrocyte physiology J:58019
abnormal synapse morphology J:43043
atherosclerotic lesions J:16573, J:40136, J:41510, J:80689
decreased circulating HDL cholesterol level J:16573
hyperlipidemia J:80689
increased circulating cholesterol level J:16573, J:40136, J:41510, J:80689
increased circulating LDL cholesterol level J:16573
increased circulating triglyceride level J:16573, J:80689
increased circulating VLDL cholesterol level J:16573, J:41510
increased prostaglandin level J:125376
lung inflammation J:83615
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * DBA 		abnormal cholesterol homeostasis J:75567
abnormal circulating protein level J:75567
abnormal lipid homeostasis J:75567
decreased circulating HDL cholesterol level J:75567
increased circulating cholesterol level J:75567
increased circulating phospholipid level J:75567
Apoetm1Unc/Apoetm1Unc
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		atherosclerotic lesions J:130658
Apoetm1Unc/Apoetm1Unc
Tg(Cyp21a1-Apoe)614Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		abnormal circulating cholesterol level J:130658
abnormal circulating protein level J:130658
decreased susceptibility to atherosclerosis J:130658
Apoetm1Unc/Apoetm1Unc
Tg(Cyp21a1-Apoe)619Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		abnormal circulating apolipoprotein E level J:130658
abnormal lipid level J:130658
decreased susceptibility to atherosclerosis J:130658
increased circulating cholesterol level J:130658
Apoetm4Mae/Apoetm4Mae
129S6/SvEvTac-Apoetm4Mae 		abnormal circulating lipid level J:172417
decreased body weight J:172417
decreased susceptibility to atherosclerosis J:172417
increased circulating cholesterol level J:172417
increased circulating HDL cholesterol level J:172417
increased circulating triglyceride level J:172417
increased circulating VLDL cholesterol level J:172417
Tg(Cyp21a1-Apoe)614Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased circulating cholesterol level J:130658
Tg(Cyp21a1-Apoe)619Fet/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased circulating cholesterol level J:130658
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
10/29/2024
MGI 6.24 		The Jackson Laboratory